Antioxidants Reduce Muscular Dystrophy in the <i>dy<sup>2J</sup>/dy<sup>2J</sup></i> Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe neuromuscular disorder without a cure. Using transcriptome and proteome profiling as well as functional assays, we previously demonstrated significant metabolic impairment in skeletal muscle from LAMA2-CM...
Main Authors: | Vahid M. Harandi, Bernardo Moreira Soares Oliveira, Valérie Allamand, Ariana Friberg, Cibely C. Fontes-Oliveira, Madeleine Durbeej |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/9/3/244 |
Similar Items
-
Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
by: Zandra Körner, et al.
Published: (2016-01-01) -
Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics
by: Pamela Barraza-Flores, et al.
Published: (2020-02-01) -
Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy.
by: S Pasteuning-Vuhman, et al.
Published: (2018-01-01) -
Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy.
by: Qing Yu, et al.
Published: (2013-01-01) -
Determination of Thermoluminescence Kinetic Parameters of La<sub>2</sub>O<sub>3</sub> Doped with Dy<sup>3+</sup> and Eu<sup>3+</sup>
by: Mahmoud Bakr, et al.
Published: (2020-02-01)